Investigation Into the Scar Reduction Potential of Prevascar (Interleukin-10)

Summary

The purpose of this study was to investigate the scar-reducing properties of eight doses of intradermal Prevascar (IL-10).

Conditions

• Cicatrix
• Wound Healing

Interventions

DRUG

Prevascar

Intradermal Prevascar, 5ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later

DRUG

Prevascar

Intradermal Prevascar, 50ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later

DRUG

Prevascar

Intradermal Prevascar, 250ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later

DRUG

Prevascar

Intradermal Prevascar, 1000ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later

DRUG

Prevascar

Intradermal Prevascar, 25ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later

DRUG

Prevascar

Intradermal Prevascar, 125ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later

DRUG

Prevascar

Intradermal Prevascar, 500ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later

DRUG

Prevascar

Intradermal Prevascar, 2000ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later

DRUG

Placebo

Intradermal Placebo, 100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later

Sponsors & Collaborators

• Renovo

  lead INDUSTRY

Principal Investigators

• James Bush · Renovo

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

85 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2005-04-30

Primary Completion

2006-11-30

Completion

2006-11-30

Countries

• United Kingdom

Study Locations